Literature DB >> 8685238

Wild-type and mutant retinoblastoma protein in paraffin sections.

J Geradts1, R A Kratzke, S Crush-Stanton, S F Wen, C E Lincoln.   

Abstract

Inactivation of the retinoblastoma susceptibility (RB) gene plays a role in the pathogenesis of a variety of human malignancies. Recently, it has become feasible to study RB expression in archival tissues, and it is expected that immunohistochemical studies on routinely processed tumors will further elucidate the biologic and clinical significance of RB mutations. Our study was designed to address two issues that are critical for the interpretation of such studies, i.e., whether mutant RB protein (pRB) can reliably be distinguished from normal pRB and whether there are significant differences in the performance characteristics of various anti-RB antibodies. We studied cell blocks of 26 mutant RB cell lines (11 lines without any RB expression, nine lines expressing truncated mRNA/pRB, six lines carrying missense mutations) with five different anti-RB monoclonal antibodies, using a recently described procedure that includes an antigen retrieval step. The specific staining pattern for pRB was nuclear. Cytoplasmic staining was found to be nonspecific and could be strong. Some truncated and all full-length mutant pRBs localized to the nucleus, creating positive nuclear staining that might be indistinguishable from the staining pattern of cells carrying wild-type RB. The five antibodies tested showed significant differences in sensitivity, specificity, and background reactivity. Our data suggest that a significant subset of mutant pRB has preserved nuclear translocation capacity, that not all anti-RB antibodies are equally suitable for immunohistochemical analysis of RB expression, and that any such analysis is bound to include a certain, albeit probably small, number of positive stains, despite the absence of functional pRB.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8685238

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  10 in total

1.  Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product.

Authors:  M L Gulley; J M Nicholls; B G Schneider; M B Amin; J Y Ro; J Geradts
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

2.  p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma.

Authors:  G Busatto; Y H Shiao; A R Parenti; R Baffa; A Ruol; M Plebani; M Rugge
Journal:  Mol Pathol       Date:  1998-04

3.  High frequency of aberrant p16(INK4A) expression in human breast cancer.

Authors:  J Geradts; P A Wilson
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

4.  Analysis of the Cycilin D1/p16/pRb Pathway in Parathyroid Adenomas.

Authors:  Eva Cristobal; Begona Arribas; Juan Tardio; Jose A. AIcazar; Juan C. Matinez-Montero; Rafael Carrion; Jose R. Polo; Laura Gil; Marta Azanedo; Jose M. Rojas; Javier Menarguez
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

5.  An immunohistochemical study of retinoblastoma gene product in normal, premalignant and malignant tissues of the uterine cervix.

Authors:  M D Noraini; M A Siti-Aishah; S W Kwan
Journal:  Malays J Med Sci       Date:  2003-01

6.  Altered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung Cancer.

Authors:  Weiqiang Zhao; Cheng C Huang; Gregory A Otterson; Marino E Leon; Yan Tang; Konstantin Shilo; Miguel A Villalona
Journal:  J Oncol       Date:  2012-04-30       Impact factor: 4.375

7.  The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma.

Authors:  H Tsuda; K Yamamoto; T Inoue; I Uchiyama; N Umesaki
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

8.  G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder.

Authors:  G A Niehans; R A Kratzke; M K Froberg; D M Aeppli; P L Nguyen; J Geradts
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

9.  Comparative analysis of Rb1, P16 and ER as diagnostic, prognostic and potential targets for therapeutic agents in ovarian epithelial tumors: an immunohistochemical study of 130 ovarian carcinomas.

Authors:  Donna Catherine Ferguson; Daniel Jerad Long; Megan Christine Smith; Laura Deeanne Craig-Owens; Julie Means; Oluwole Fadare; Mohamed Mokhtar Desouki
Journal:  J Ovarian Res       Date:  2015-06-05       Impact factor: 4.234

10.  The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells.

Authors:  Mark P Labrecque; Mandeep K Takhar; Rebecca Nason; Stephanie Santacruz; Kevin J Tam; Shabnam Massah; Anne Haegert; Robert H Bell; Manuel Altamirano-Dimas; Colin C Collins; Frank J S Lee; Gratien G Prefontaine; Michael E Cox; Timothy V Beischlag
Journal:  Oncotarget       Date:  2016-04-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.